|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *Table S7. Reasons for discontinuation of people withdrawing therapy with non-specific immunoglobulins, by level of evidence based on SISCAT's guidelines, ageband and hospital. Number of discontinuers per level of evidence, ageband and hospital are used as denominator. Empty cells mean no cases were identified.* | | | | | | | | | | | | | |
|  | **BUH (n=34)** | | | | **GTiPUH (n=18)** | | | | **VHUH (n=99)** | | | |  |
| **Reasons for discontinuation** | **A** | **B** | **C** | **Unknown** | **A** | **B** | **C** | **Unknown** | **A** | **B** | **C** | **Unknown** |  |
| ***Adults (≥18 years of age)*** | | | | | | | | | | | | | **TOTAL ADULTS, n(%)** |
| Remission | 9 (32.1) | 1 (33.4) | 2 (100) |  | 3 (37.5) | 2 (40.0) |  | 1 (50.0) | 11 (25.0) | 2 (12.5) |  | 2 (33.4) | **33 (28.5)** |
| No response | 5 (17.9) |  |  |  | 2 (25.0) |  |  |  | 11 (25.0) | 4 (25.0) |  | 1 (16.7) | **23 (19.8)** |
| Death | 2 (7.1) | 2 (66.6) |  |  | 1 (12.5) | 1 (20.0) |  |  | 7 (15.9) | 3 (18.7) | 1 (100) | 1 (16.7) | **18 (15.5)** |
| Moved | 2 (7.1) |  |  |  |  |  |  |  | 4 (9.1) | 3 (18.7) |  |  | **9 (7.8)** |
| Lost Follow | 5 (17.9) |  |  | 1 (100) |  |  |  |  | 1 (2.3) |  |  |  | **7 (6.0)** |
| Toxicity | 1 (3.6) |  |  |  | 1 (12.5) |  |  | 1 (50.0) | 3 (6.8) |  |  |  | **6 (5.2)** |
| Comorbility |  |  |  |  | 1 (12.5) |  |  |  | 2 (4.5) | 1 (6.3) |  | 1 (16.7) | **5 (4.3)** |
| No adherence | 2 (7.1) |  |  |  |  | 1 (20.0) |  |  | 1 (2.3) |  |  |  | **4 (3.5)** |
| Patient decision | 1 (3.6) |  |  |  |  |  |  |  | 1 (2.3) | 1 (6.3) |  | 1 (16.7) | **4 (3.5)** |
| No venous access | 1 (3.6) |  |  |  |  |  |  |  |  | 1 (6.3) |  |  | **2 (1.7)** |
| Interaction |  |  |  |  |  | 1 (20.0) |  |  | 1 (2.3) |  |  |  | **2 (1.7)** |
| Progresion |  |  |  |  |  |  |  |  |  | 1 (6.3) |  |  | **1 (0.9)** |
| Surgery |  |  |  |  |  |  |  |  | 1 (2.3) |  |  |  | **1 (0.9)** |
| Clinical trial |  |  |  |  |  |  |  |  | 1 (2.3) |  |  |  | **1 (0.9)** |
| Pregnancy |  |  |  |  |  |  |  |  |  |  |  |  | **0 (0)** |
| **TOTAL PER LoE** | **28 (82.4)** | **3 (8.8)** | **2 (5.9)** | **1 (2.9)** | **8 (53.3)** | **5 (33.3)** | **0 (0)** | **2 (13.4)** | **44 (65.7)** | **16 (23.8)** | **1 (1.5)** | **6 (9.0)** | **116 (100)** |
| **TOTAL ADULTS PER HOSPITAL** | **34 (29.3)** | | | | **15 (12.9)** | | | | **67 (57.8)** | | | |
|  | | | | | | | | | | | | | |
| ***Pediatrics (<18 years of age)*** | | | | | | | | | | | | | **TOTAL PEDIATRICS, n(%)** |
| Remission |  |  |  |  |  |  |  |  | 13 (50.0) |  |  |  | **13 (37.1)** |
| No response |  |  |  |  | 2 (66.6) |  |  |  | 4 (15.4) | 1 (50.0) |  | 1 (25.0) | **8 (22.9)** |
| Moved |  |  |  |  |  |  |  |  | 4 (15.4) |  |  |  | **4 (11.4)** |
| No adherence |  |  |  |  | 1 (33.4) |  |  |  | 1 (3.8) | 1 (50.0) |  |  | **3 (8.6)** |
| Death |  |  |  |  |  |  |  |  | 1 (3.8) |  |  | 1 (25.0) | **2 (5.7)** |
| Lost Follow |  |  |  |  |  |  |  |  | 1 (3.8) |  |  | 1 (25.0) | **2 (5.7)** |
| Comorbility |  |  |  |  |  |  |  |  |  |  |  | 1 (25.0) | **1 (2.9)** |
| Toxicity |  |  |  |  |  |  |  |  | 1 (3.8) |  |  |  | **1 (2.9)** |
| Progresion |  |  |  |  |  |  |  |  | 1 (3.8) |  |  |  | **1 (2.9)** |
| Other reasons\* |  |  |  |  |  |  |  |  |  |  |  |  | **0 (0)** |
| **TOTAL PER LoE** | **0 (0)** | **0 (0)** | **0 (0)** | **0 (0)** | **3 (100)** | **0 (0)** | **0 (0)** | **0 (0)** | **26 (81.3)** | **2 (6.3)** | **0 (0)** | **4 (12.5)** | **35 (100)** |
| **TOTAL PEDIATRICS PER HOSPITAL** | **0 (0)** | | | | **3 (8.6)** | | | | **32 (91.4)** | | | |
| *\*Other reasons include: patient decision, surgery, clinical trial, pregnancy, no venous access or interaction.* | | | | | | | | | | | | |  |
| *BUH: Bellvitge University Hospital; GTiPUH: Germans Trias i Pujol University Hospital; VHUH: Vall d'Hebron University Hospital* | | | | | | | | | | | | | |